The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer

被引:142
作者
Sellers, TA [1 ]
Mink, PJ [1 ]
Cerhan, JR [1 ]
Zheng, W [1 ]
Anderson, KE [1 ]
Kushi, LH [1 ]
Folsom, AR [1 ]
机构
[1] UNIV IOWA, IOWA CITY, IA 52242 USA
关键词
D O I
10.7326/0003-4819-127-11-199712010-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The risks and benefits of hormone replacement therapy (HRT) are of considerable interest and importance, especially in terms of whether they differ among subsets of women. Objective: To determine whether HRT is associated with increased risks for breast cancer and total mortality in women with a family history of breast cancer. Design: Prospective cohort study. Setting: Population-based sample of midwestern post-menopausal women enrolled in an observational study of risk factors for cancer. Participants: Random sample of 41 837 female Iowa residents 55 to 69 years of age. Measurements: Incidence rates of and relative risks for breast cancer (n = 1085) and total mortality (n = 2035) th rough 8 years of follow-up were calculated by using data from the State Health Registry of Iowa and the National Death Index. Results: A family history of breast cancer was reported by 12.2% of the cohort at risk. Among women with a family history of breast cancer, those who currently used HRT and had done so for at least 5 years developed breast cancer at an age-adjusted annual rate of 61 cases per 10 000 person-years (95% CI, 28 to 94 cases); this rate was not statistically significantly higher than the rate in women who had never used HRT (46 cases per 10 000 person-years ICI, 36 to 55 cases]). Among women with a family history, those who used HRT had a significantly lower risk for total mortality than did women who had never used HRT (relative risk, 0.67 [CI, 0.51 to 0.89]), including total cancer-related mortality (relative risk, 0.75 [CI, 0.50 to 1.12]). The age-adjusted annual mortality rate for women using HRT for at least 5 years was 46 deaths per 10 000 person-years (CI, 19 to 74 deaths); this is roughly half the rate seen in women who had never used HRT (80 deaths per In 000 person-years [CI, 69 to 92 deaths]). Conclusions: These data suggest that HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate.
引用
收藏
页码:973 / 980
页数:8
相关论文
共 43 条
[1]  
[Anonymous], 1997, INT CLASSIFICATION D
[2]  
[Anonymous], 1994, NIH PUBLICATION, V94-3157
[3]   ESTROGEN THERAPY AFTER THE MENOPAUSE - BOON OR BANE [J].
ARMSTRONG, BK .
MEDICAL JOURNAL OF AUSTRALIA, 1988, 148 (05) :213-214
[4]   MORTALITY AND CANCER RATES IN NONRESPONDENTS TO A PROSPECTIVE-STUDY OF OLDER WOMEN - 5-YEAR FOLLOW-UP [J].
BISGARD, KM ;
FOLSOM, AR ;
HONG, CP ;
SELLERS, TA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 139 (10) :990-1000
[5]  
BLACKMAN JA, 1995, NEW ENGL J MED, V333, P1355
[6]  
Breslow NE, 1987, STATISTICAL METHODS, VII
[7]   ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER RISK [J].
BRINTON, LA ;
SCHAIRER, C .
EPIDEMIOLOGIC REVIEWS, 1993, 15 (01) :66-79
[8]   MENOPAUSAL ESTROGENS AND BREAST-CANCER RISK - AN EXPANDED CASE-CONTROL STUDY [J].
BRINTON, LA ;
HOOVER, R ;
FRAUMENI, JF .
BRITISH JOURNAL OF CANCER, 1986, 54 (05) :825-832
[9]  
BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO
[10]  
2-L